CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- 4 Open-market sale Chief Medical Officer sold 6,580 shares at $14.35 ($94,418)
- 144 Insider Sale of Securities
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Open-market sale Co-Chief Executive Officer sold 29,975 shares at an average $14.38 ($430,952)
- 4 Open-market sale Chief Legal Officer sold 8,828 shares at $14.58 ($128,669)
- 4 Open-market sale Chief Financial Officer sold 10,558 shares at $14.65 ($154,650)
- 4 Open-market sale Co-Chief Executive Officer sold 29,933 shares at an average $14.35 ($429,469)
- 4 Open-market sale Chief Medical Officer sold 12,039 shares at $14.58 ($175,518)
- 8-K Event Material agreement
- 424B5 Offering Prospectus
- 424B5 Offering Prospectus
- 8-K Event Other events
- 4 Planned sale Chief Legal Officer sold 30,000 shares at an average $8.20 ($246,149)
Page 6 of 23 · 446 filings